TGA Approval

OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion (391349)

ARTG ID

391349

ARTG Name

OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion

Sponsor

Eli Lilly Australia Pty Ltd

ARTG Date

September 27, 2023

Registration Type

Medicine

Therapeutic Good Type

Medicine

Licence Status

Active

Licence Category

Registered

Sponsor Information

Sponsor Name

Sponsor Item Name

ELI LILLY AUSTRALIA PTY LTD

Ingredient Name

mirikizumab

Empowering clinical research with data-driven insights and AI-powered tools.

OMVOH mirikizumab 300 mg/15 mL (20 mg/mL) concentrated injection vial for IV infusion (391349) - TGA 批准文号 | MedPath